NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM) Valuation After FDA Alignment On Accelerated Pathway For BEAM-302
Beam Therapeutics (BEAM) is back in focus after securing regulatory alignment with the FDA on an accelerated approval pathway for its BEAM-302 program targeting alpha-1 antitrypsin deficiency, sharpening attention on upcoming data.
See our latest analysis for Beam Therapeutics.
The regulatory alignment on BEAM-302 has arrived alongside a strong 1-month share price return of 23.37% and a 1-year total shareholder return of 30.32%. However, the 3-year and 5-year total shareholder returns of...